Authors
Latest:
Dr. Albala on the Advantages of PSMA-PET Imaging in Prostate CancerDavid Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.
Latest:
Dr. Arenberg on Low-Cost Intervention to Improve Tobacco Cessation for Lung CancerDavid Arenberg, MD, associate professor, Department of Internal Medicine at the University of Michigan, discusses preliminary results of a low-cost intervention to improve tobacco cessation practices within a large university health system.
Latest:
Dr. Page on Hormone-Directed Strategies in Triple-Negative Breast CancerDavid B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).
Latest:
Developing Alternative Payment Models That Providers and Commercial Payers SupportAlthough some of the improvement is a result of prevention and screening, advances in technology and in chemotherapy and immunotherapy pharmaceuticals have been major driving forces in the decline in cancer-related death.
Latest:
Dr. Madoff on Selecting Patients With HCC Appropriate for Minimally Invasive TherapyDavid C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.
Latest:
Dr. Metz Discusses Using a Multidisciplinary Approach When Treating NETsDavid C. Metz, MBBCh, professor of medicine, co-director, GI Physiology laboratory, Hospital of the University of Pennsylvania, discusses using a multidisciplinary approach to treating neuroendocrine tumors (NETs).
Latest:
Dr. Metz on Increasing Incidence of Neuroendocrine TumorsDavid C. Metz, MD, gastroenterologist, University of Pennsylvania School of Medicine, associate chief, Medical Affairs, Division of Gastroenterology, discusses the increasing incidence of neuroendocrine tumors.
Latest:
Dr. Portnoy on the Importance of Driver Mutations in the Treatment of NSCLCDavid C. Portnoy, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of driver mutations in the treatment of non–small cell lung cancer (NSCLC).
Latest:
Dr. Carbone on Pivotal Immunotherapy Studies in Lung CancerDavid Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer in Barcelona, Spain.
Latest:
Dr. Cella on Patient-Reported Outcomes in a Clinical SettingDr. David Cella from Northwestern University Feinberg School of Medicine on Patient-Reported Outcomes in a Clinical Setting
Latest:
Dr. Cibula on Adding Dendritic Cell-Based Immunotherapy to Chemotherapy in Ovarian CancerDavid Cibula, MD, a gynecologic oncologist at the Gynaecologic Center of Charles University, discusses a trial that examined the addition of dendritic cell-based immunotherapy to chemotherapy in patients with relapsed ovarian cancer.
Latest:
Dr. Chang on the TRINOVA-1 Trial in Ovarian CancerDavid D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.
Latest:
Dr. Thiel on Protecting Patients and Providers From COVID-19David D. Thiel, MD, chair, discusses the measures that are being taken to protect patients and providers from the coronavirus disease 2019 (COVID-19).
Latest:
Big Data Era Arrives in Clinical Practice Via CancerLinQ ProjectThis new approach—with a focus on personalized, data-driven decisions—is remaking healthcare, and more specifically, changing how oncologists treat cancer.
Latest:
Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple MyelomaDavid E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.
Latest:
Dr. David Eagle on Cost-Drivers in OncologyDavid Eagle, MD, past president of the Community Oncology Alliance (COA) and partner in Lake Norman Oncology, Mooresville, North Carolina, discuss controlling costs of cancer treatment.
Latest:
Dr McDermott on the Eligibility Criteria of the LITESPARK-024 Trial in RCCDavid F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.
Latest:
Series Wrap-up: Novel Therapies for mRCCA panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
Latest:
Dr. Penson on Ongoing Research in Prostate CancerDavid F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.
Latest:
Dr. Penson on Ongoing Research in Prostate CancerDavid F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.
Latest:
Dr. Maloney on the Value of CAR T Cells in Relapsed/Refractory Aggressive LymphomasDavid G. Maloney, MD, PhD, discusses the value of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive lymphomas.
Latest:
Dr. Ilson on the Utility of Zolbetuximab in Claudin-Positive Gastric CancersDavid H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric cancers.
Latest:
Ponatinib Continues March to Potential Front-line Use in CMLPACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.
Latest:
Dr. Hyman on MEDI3617 as Potential Treatment for Patients with Advanced Solid TumorsDavid Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.
Latest:
Dr. Quinn on Targetable Molecular Pathways in RCCDavid I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.
